Abstract:The purpose of the research is to examine the advantages and difficulties of target-site drug delivery methods, with an emphasis on the application of polyethylene glycol (PEG) to enhance drug solubility, bioavailability, and immune response characteristics. It has been demonstrated that this method lowers immunogenicity, enhances pharmacokinetics, and helps drugs pass the blood-brain barrier while reducing reticuloendothelial system clearance. PEG and its derivatives are being used more and more to alter therapeutic substances, offering an escape from some of the drawbacks of conventional medication formulations. In the review, different PEGylation tactics are examined, including cutting-edge methods for reversing multi-drug resistance in nanocarriers. PEGylation has a number of benefits, but there are still drawbacks, including the immunogenic reaction to PEG, which is sometimes referred to as "anti-PEG antibodies," and stability problems that call for the creation of countermeasures. The study devotes a large amount of its space to listing FDA-approved PEGylated medications, emphasizing their therapeutic advantages and clinical uses in a range of medical specialties. The research also explores the regulatory environment that surrounds PEG, closely examining its effectiveness and safety in medication compositions. The review goes beyond PEGylation and includes lipid-based nanocarriers, including liposomes, nanostructured lipid carriers (NLCs), and solid lipid nanoparticles (SLNs). Because these nanocarriers can target specific tissues or cells, improve bioavailability, and encapsulate pharmaceuticals, they are becoming more and more significant in drug delivery systems. The Target Product Profile (TPP) and Quality by Design (QbD) principles serve as the foundation for the creation and characterization of these lipid-based systems. These tools direct the methodical assessment of material properties and risk assessments during the formulation phase. This method guarantees that the finished product satisfies the appropriate requirements for efficacy, safety, and quality. The regulatory status and safety profile of nano lipid carriers are covered in the paper's conclusion, which emphasizes the importance of careful examination and oversight in bringing these cutting-edge products to market. Overall, this thorough analysis highlights the revolutionary potential of lipid-based nanocarriers and PEGylation in improving drug delivery and therapeutic efficacy, but it also draws attention to the continued difficulties and legal issues that need to be resolved in order to fully reap the benefits of these technologies in biomedicine.

Site-Specific PEGylation of Protein Drugs

The Technique and Clinical Development of Site-specific PEGylated Protein Drugs

A Novel Zwitterionic Copolymer with A Short Poly(Methyl Acrylic Acid) Block for Improving Both Conjugation and Separation Efficiency of A Protein Without Losing Its Bioactivity

PEG Modification of Protein Drug

Site-Directed Modification of Genetically Engineered Proteus Sp Lipase K107 Variants with A Polyethylene Glycol Derivative

Discrete Polyethylene Glycol Derivatives As a Potent Impetus for Next-Generation Biomedicines

PEGylated therapeutics in the clinic

Research progress on the PEGylation of therapeutic proteins and peptides (TPPs)

PEGylation in Pharmaceutical Development: Current Status and Emerging Trends in Macromolecular and Immunotherapeutic Drugs

Advances in PEGylation of Drug Conjugates

Site-specific N-terminal PEGylation-based controlled release of biotherapeutics: An application for GLP-1 delivery to improve pharmacokinetics and prolong hypoglycemic effects

Non-covalent PEGylation of proteins mediated by site-specific in situ polymerization induced co-assembly

Emerging trends of discrete Poly(ethylene glycol) in biomedical applications

Structure-Based Site-Specific PEGylation of Fibroblast Growth Factor 2 Facilitates Rational Selection of Conjugate Sites.

In vivo metabolism and safety evaluation of PEGylated proteins drugs

Achievements and Bottlenecks of PEGylation in Nano-delivery Systems

PEGYLATION: an important approach for novel drug delivery system

Characterization of a site-specific PEGylated analog of exendin-4 and determination of the PEGylation site.

Site-specific in Situ Growth of an Interferon-Polymer Conjugate That Outperforms PEGASYS in Cancer Therapy.

The Effect of PEG-modification on the Pharmacokinetics of Protein and the Related Pharmacokinetic Research Methods

Moving Protein PEGylation from an Art to a Data Science